126
|
Giannini LAA, Peterson C, Ohm D, Xie SX, McMillan CT, Raskovsky K, Massimo L, Suh E, Van Deerlin VM, Wolk DA, Trojanowski JQ, Lee EB, Grossman M, Irwin DJ. Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology. Acta Neuropathol Commun 2021; 9:30. [PMID: 33622418 PMCID: PMC7901087 DOI: 10.1186/s40478-021-01129-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2021] [Accepted: 02/07/2021] [Indexed: 01/10/2023] Open
Abstract
Frontotemporal lobar degeneration proteinopathies with tau inclusions (FTLD-Tau) or TDP-43 inclusions (FTLD-TDP) are associated with clinically similar phenotypes. However, these disparate proteinopathies likely differ in cellular severity and regional distribution of inclusions in white matter (WM) and adjacent grey matter (GM), which have been understudied. We performed a neuropathological study of subcortical WM and adjacent GM in a large autopsy cohort (n = 92; FTLD-Tau = 37, FTLD-TDP = 55) using a validated digital image approach. The antemortem clinical phenotype was behavioral-variant frontotemporal dementia (bvFTD) in 23 patients with FTLD-Tau and 42 with FTLD-TDP, and primary progressive aphasia (PPA) in 14 patients with FTLD-Tau and 13 with FTLD-TDP. We used linear mixed-effects models to: (1) compare WM pathology burden between proteinopathies; (2) investigate the relationship between WM pathology burden and WM degeneration using luxol fast blue (LFB) myelin staining; (3) study regional patterns of pathology burden in clinico-pathological groups. WM pathology burden was greater in FTLD-Tau compared to FTLD-TDP across regions (beta = 4.21, SE = 0.34, p < 0.001), and correlated with the degree of WM degeneration in both FTLD-Tau (beta = 0.32, SE = 0.10, p = 0.002) and FTLD-TDP (beta = 0.40, SE = 0.08, p < 0.001). WM degeneration was greater in FTLD-Tau than FTLD-TDP particularly in middle-frontal and anterior cingulate regions (p < 0.05). Distinct regional patterns of WM and GM inclusions characterized FTLD-Tau and FTLD-TDP proteinopathies, and associated in part with clinical phenotype. In FTLD-Tau, WM pathology was particularly severe in the dorsolateral frontal cortex in nonfluent-variant PPA, and GM pathology in dorsolateral and paralimbic frontal regions with some variation across tauopathies. Differently, FTLD-TDP had little WM regional variability, but showed severe GM pathology burden in ventromedial prefrontal regions in both bvFTD and PPA. To conclude, FTLD-Tau and FTLD-TDP proteinopathies have distinct severity and regional distribution of WM and GM pathology, which may impact their clinical presentation, with overall greater severity of WM pathology as a distinguishing feature of tauopathies.
Collapse
|
127
|
Wisse LEM, Ungrady MB, Ittyerah R, Lim SA, Yushkevich PA, Wolk DA, Irwin DJ, Das SR, Grossman M. Cross-sectional and longitudinal medial temporal lobe subregional atrophy patterns in semantic variant primary progressive aphasia. Neurobiol Aging 2021; 98:231-241. [PMID: 33341654 PMCID: PMC8018475 DOI: 10.1016/j.neurobiolaging.2020.11.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Revised: 11/13/2020] [Accepted: 11/16/2020] [Indexed: 10/22/2022]
Abstract
T1-magnetic resonance imaging (MRI) studies report early atrophy in the left anterior temporal lobe, especially the perirhinal cortex, in semantic variant primary progressive aphasia (svPPA). Improved segmentation protocols using high-resolution T2-MRI have enabled fine-grained medial temporal lobe (MTL) subregional measurements, which may provide novel information on the atrophy pattern and disease progression in svPPA. We aimed to investigate the MTL subregional atrophy pattern cross-sectionally and longitudinally in patients with svPPA as compared with controls and patients with Alzheimer's disease (AD). MTL subregional volumes were obtained using the Automated Segmentation for Hippocampal Subfields software from high-resolution T2-MRIs in 15 svPPA, 37 AD, and 23 healthy controls. All MTL volumes were corrected for intracranial volume and parahippocampal cortices for slice number. Longitudinal atrophy rates of all subregions were obtained using an unbiased deformation-based morphometry pipeline in 6 svPPA patients, 9 controls, and 12 AD patients. Cross-sectionally, significant volume loss was observed in svPPA compared with controls in the left MTL, right cornu ammonis 1 (CA1), Brodmann area (BA)35, and BA36 (subdivisions of the perirhinal cortex). Compared with AD patients, svPPA patients had significantly smaller left CA1, BA35, and left and right BA36 volumes. Longitudinally, svPPA patients had significantly greater atrophy rates of left and right BA36 than controls but not relative to AD patients. Fine-grained analysis of MTL atrophy patterns provides information about the evolution of atrophy in svPPA. These results indicate that MTL subregional measures might be useful markers to track disease progression or for clinical trials in svPPA.
Collapse
|
128
|
Germann J, Elias GJB, Boutet A, Narang K, Neudorfer C, Horn A, Loh A, Deeb W, Salvato B, Almeida L, Foote KD, Rosenberg PB, Tang-Wai DF, Wolk DA, Burke AD, Salloway S, Sabbagh MN, Chakravarty MM, Smith GS, Lyketsos CG, Okun MS, Lozano AM. Brain structures and networks responsible for stimulation-induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease. Alzheimers Dement 2021; 17:777-787. [PMID: 33480187 PMCID: PMC8247976 DOI: 10.1002/alz.12238] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Revised: 09/24/2020] [Accepted: 10/22/2020] [Indexed: 12/11/2022]
Abstract
Introduction Fornix deep brain stimulation (fx‐DBS) is under investigation for treatment of Alzheimer's disease (AD). We investigated the anatomic correlates of flashback phenomena that were reported previously during acute diencephalic stimulation. Methods Thirty‐nine patients with mild AD who took part in a prior fx‐DBS trial (NCT01608061) were studied. After localizing patients’ implanted electrodes and modeling the volume of tissue activated (VTA) by DBS during systematic stimulation testing, we performed (1) voxel‐wise VTA mapping to identify flashback‐associated zones; (2) machine learning–based prediction of flashback occurrence given VTA overlap with specific structures; (3) normative functional connectomics to define flashback‐associated brain‐wide networks. Results A distinct diencephalic region was associated with greater flashback likelihood. Fornix, bed nucleus of stria terminalis, and anterior commissure involvement predicted memory events with 72% accuracy. Flashback‐inducing stimulation exhibited greater functional connectivity to a network of memory‐evoking and autobiographical memory‐related sites. Discussion These results clarify the neuroanatomical substrates of stimulation‐evoked flashbacks.
Collapse
|
129
|
Walker JM, Richardson TE, Farrell K, Iida MA, Foong C, Shang P, Attems J, Ayalon G, Beach TG, Bigio EH, Budson A, Cairns NJ, Corrada M, Cortes E, Dickson DW, Fischer P, Flanagan ME, Franklin E, Gearing M, Glass J, Hansen LA, Haroutunian V, Hof PR, Honig L, Kawas C, Keene CD, Kofler J, Kovacs GG, Lee EB, Lutz MI, Mao Q, Masliah E, McKee AC, McMillan CT, Mesulam MM, Murray M, Nelson PT, Perrin R, Pham T, Poon W, Purohit DP, Rissman RA, Sakai K, Sano M, Schneider JA, Stein TD, Teich AF, Trojanowski JQ, Troncoso JC, Vonsattel JP, Weintraub S, Wolk DA, Woltjer RL, Yamada M, Yu L, White CL, Crary JF. Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. J Neuropathol Exp Neurol 2021; 80:102-111. [PMID: 33367843 PMCID: PMC8453611 DOI: 10.1093/jnen/nlaa153] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Primary age-related tauopathy (PART) is a neurodegenerative entity defined as Alzheimer-type neurofibrillary degeneration primarily affecting the medial temporal lobe with minimal to absent amyloid-β (Aβ) plaque deposition. The extent to which PART can be differentiated pathoanatomically from Alzheimer disease (AD) is unclear. Here, we examined the regional distribution of tau pathology in a large cohort of postmortem brains (n = 914). We found an early vulnerability of the CA2 subregion of the hippocampus to neurofibrillary degeneration in PART, and semiquantitative assessment of neurofibrillary degeneration in CA2 was significantly greater than in CA1 in PART. In contrast, subjects harboring intermediate-to-high AD neuropathologic change (ADNC) displayed relative sparing of CA2 until later stages of their disease course. In addition, the CA2/CA1 ratio of neurofibrillary degeneration in PART was significantly higher than in subjects with intermediate-to-high ADNC burden. Furthermore, the distribution of tau pathology in PART diverges from the Braak NFT staging system and Braak stage does not correlate with cognitive function in PART as it does in individuals with intermediate-to-high ADNC. These findings highlight the need for a better understanding of the contribution of PART to cognitive impairment and how neurofibrillary degeneration interacts with Aβ pathology in AD and PART.
Collapse
|
130
|
Cousins KAQ, Irwin DJ, Wolk DA, Lee EB, Shaw LMJ, Trojanowski JQ, Da Re F, Gibbons GS, Grossman M, Phillips JS. ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration. Brain 2020; 143:2295-2311. [PMID: 32666090 DOI: 10.1093/brain/awaa165] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Revised: 02/27/2020] [Accepted: 03/27/2020] [Indexed: 12/13/2022] Open
Abstract
Under the ATN framework, CSF analytes provide evidence of the presence or absence of Alzheimer's disease pathological hallmarks: amyloid plaques (A), phosphorylated tau (T), and accompanying neurodegeneration (N). Still, differences in CSF levels across amnestic and non-amnestic variants or due to co-occurring pathologies might lead to misdiagnoses. We assess the diagnostic accuracy of CSF markers for amyloid, tau, and neurodegeneration in an autopsy cohort of 118 Alzheimer's disease patients (98 amnestic; 20 non-amnestic) and 64 frontotemporal lobar degeneration patients (five amnestic; 59 non-amnestic). We calculated between-group differences in CSF concentrations of amyloid-β1-42 peptide, tau protein phosphorylated at threonine 181, total tau, and the ratio of phosphorylated tau to amyloid-β1-42. Results show that non-amnestic Alzheimer's disease patients were less likely to be correctly classified under the ATN framework using independent, published biomarker cut-offs for positivity. Amyloid-β1-42 did not differ between amnestic and non-amnestic Alzheimer's disease, and receiver operating characteristic curve analyses indicated that amyloid-β1-42 was equally effective in discriminating both groups from frontotemporal lobar degeneration. However, CSF concentrations of phosphorylated tau, total tau, and the ratio of phosphorylated tau to amyloid-β1-42 were significantly lower in non-amnestic compared to amnestic Alzheimer's disease patients. Receiver operating characteristic curve analyses for these markers showed reduced area under the curve when discriminating non-amnestic Alzheimer's disease from frontotemporal lobar degeneration, compared to discrimination of amnestic Alzheimer's disease from frontotemporal lobar degeneration. In addition, the ATN framework was relatively insensitive to frontotemporal lobar degeneration, and these patients were likely to be classified as having normal biomarkers or biomarkers suggestive of primary Alzheimer's disease pathology. We conclude that amyloid-β1-42 maintains high sensitivity to A status, although with lower specificity, and this single biomarker provides better sensitivity to non-amnestic Alzheimer's disease than either the ATN framework or the phosphorylated-tau/amyloid-β1-42 ratio. In contrast, T and N status biomarkers differed between amnestic and non-amnestic Alzheimer's disease; standard cut-offs for phosphorylated tau and total tau may thus result in misclassifications for non-amnestic Alzheimer's disease patients. Consideration of clinical syndrome may help improve the accuracy of ATN designations for identifying true non-amnestic Alzheimer's disease.
Collapse
|
131
|
Rabinovici GD, Iaccarino L, La Joie R, Lesman‐Segev OH, Soleimani‐Meigooni DN, Provost K, Collins JA, Aisen PS, Borowski BJ, Eloyan A, Fagan A, Foroud TM, Gatsonis C, Jack CR, Kramer JH, Saykin AJ, Toga AW, Vemuri P, Day GS, Graff‐Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez MF, Onyike CU, Rogalski EJ, Salloway SP, Wolk DA, Wingo TS, Koeppe RA, Dickerson BC, Carrillo MC, Apostolova LG. Amyloid and tau PET in sporadic early‐onset Alzheimer’s disease: Preliminary results from LEADS. Alzheimers Dement 2020. [DOI: 10.1002/alz.041613] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
132
|
Wisse L, Ravikumar S, Ittyerah R, Lim SA, Lane J, Lavery M, Xie L, Robinson JL, Schuck T, Grossman M, Lee EB, Tisdall DM, Prabhakaran K, Detre JA, Das SR, Mizsei G, Artacho‐Perula E, Martin MMIDO, Jimenez MDMA, Munoz M, Romero FJM, Rabal MDPM, Sanchez SC, Gonzalez JCD, Prieto CDLR, Parada MC, Irwin DJ, Trojanowski JQ, Wolk DA, Insausti R, Yushkevich PA. High‐resolution postmortem MRI reveals TDP‐43 association with medial temporal lobe subregional atrophy. Alzheimers Dement 2020. [DOI: 10.1002/alz.045744] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
133
|
Ezzati A, Davatzikos C, Wolk DA, Aisen PS, Lipton RB. Is it time to use predictive models to boost power of Alzheimer’s disease clinical trials? A post‐hoc analysis of phase 3 solanezumab trials. Alzheimers Dement 2020. [DOI: 10.1002/alz.043022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
134
|
Maroni MJ, Wolk DA, Das SR, De Flores R, Wisse L, Xie L, Yushkevich PA, Lee EB, McMillan CT. Epigenetic measurement of biological age associates with tau load in normal brain aging. Alzheimers Dement 2020. [DOI: 10.1002/alz.042068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
135
|
Flaherty R, Ezzo R, Collins JA, Krivensky S, Eckbo R, Vemuri P, Borowski BJ, Iaccarino L, La Joie R, Lesman‐Segev OH, Bourakova V, Eloyan A, Aisen PS, Fagan A, Foroud TM, Gatsonis C, Jack CR, Kramer JH, Koeppe RA, Saykin AJ, Toga AW, Day GS, Graff‐Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez MF, Onyike CU, Rogalski EJ, Salloway SP, Wolk DA, Wingo TS, Carrillo MC, Apostolova LG, Rabinovici GD, Dickerson BC. Increased white matter MRI T1 hypointensity volume in young‐onset Alzheimer’s disease patients is not accounted for by age or cardiovascular risk factors. Alzheimers Dement 2020. [DOI: 10.1002/alz.045577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
136
|
Truelove‐Hill M, Erus G, Pomponio R, Bashyam V, Doshi J, Habes M, Ezzati A, Bilgel M, Resnick SM, Nasrallah IM, Wolk DA, Davatzikos C. A predictive, modeling‐based screening tool to enrich amyloid beta positivity in a cognitively normal sample. Alzheimers Dement 2020. [DOI: 10.1002/alz.045242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
137
|
Phillips JS, Cousins KAQ, Irwin DJ, Wolk DA, Lee EB, Gibbons GS, McMillan CT, Trojanowski JQ, Grossman M. Lower neocortical tau burden distinguishes Alzheimer’s pathology occurring with vs. without primary non‐Alzheimer’s pathology. Alzheimers Dement 2020. [DOI: 10.1002/alz.046529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
138
|
Wisse L, Xie L, Das SR, De Flores R, Yushkevich P, Wolk DA. Tau pathology mediates age effects on medial temporal lobe atrophy. Alzheimers Dement 2020. [DOI: 10.1002/alz.038250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
139
|
Bezdicek O, Červenková M, Moore TM, Georgi HS, Sulc Z, Wolk DA, Weintraub DA, Moberg PJ, Jech R, Kopecek M, Roalf DR. Determining a Short Form Montreal Cognitive Assessment (s-MoCA) Czech Version: Validity in Mild Cognitive Impairment Parkinson's Disease and Cross-Cultural Comparison. Assessment 2020; 27:1960-1970. [PMID: 29929376 PMCID: PMC6274600 DOI: 10.1177/1073191118778896] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The Montreal Cognitive Assessment (MoCA) is one of the most common screening instruments for mild cognitive impairment. However, the standard MoCA is approximately two times longer to administer than the Mini-Mental State Examination. A total of 699 Czech and 175 American participants received the standard MoCA Czech and English versions and in the clinical part, a sample of 102 nondemented patients with Parkinson's disease (PD). We created a validated Czech short version (s-MoCA-CZ) from the original using item response theory. As expected, s-MoCA-CZ scores were highly correlated with the standard version (Pearson r = .94, p < .001). s-MoCA-CZ also had 80% classification accuracy in the differentiation of PD mild cognitive impairment from PD without impairment. The s-MoCA-CZ, a brief screening tool, is shorter to administer than the standard MoCA. It provides high-classification accuracy for PD mild cognitive impairment and is equivalent to that of the standard MoCA-CZ.
Collapse
|
140
|
Lasserve J, Lim SA, Wisse L, Ittyerah R, Ravikumar S, Lavery M, Robinson JL, Schuck T, Grossman M, Lee EB, Yushkevich PA, Tisdall DM, Prabhakaran K, Mizsei G, Artacho‐Perula E, Martin MMIDO, Jimenez MDMA, Munoz M, Romero FJM, Rabal MDPM, Irwin DJ, Trojanowski JQ, Wolk DA, Insausti R. Optimized extraction of the medial temporal lobe for postmortem MRI based on custom 3D printed molds. Alzheimers Dement 2020. [DOI: 10.1002/alz.043254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
141
|
de Flores R, Das SR, Xie L, Wisse L, Shah P, Yushkevich PA, Wolk DA. Neurodegeneration in medial temporal lobe subregions propagates within distinct functional networks in the AD continuum. Alzheimers Dement 2020. [DOI: 10.1002/alz.045063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
142
|
Cousins KAQ, Phillips JS, Irwin DJ, Lee EB, Wolk DA, Shaw LM, Gibbons GS, McMillan CT, Trojanowski JQ, Grossman M. ATN classifications in a mixed cohort of frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease (AD) pathology using cerebrospinal fluid neurofilament light chain (NFL). Alzheimers Dement 2020. [DOI: 10.1002/alz.039144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
143
|
Habes M, Sotiras A, Erus G, Toledo JB, Janowitz D, Wolk DA, Shou H, Bryan N, Doshi J, Voelzke H, Schminke U, Hoffmann W, Resnick SM, Grabe HJ, Davatzikos C. Data‐driven approach reveals heterogeneity and region‐specific association of white matter hyperintensities with the APOE genotype. Alzheimers Dement 2020. [DOI: 10.1002/alz.037342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
144
|
Srinivasan D, Truelove‐Hill M, Erus G, Sotiras A, Doshi J, Wolk DA, Davatzikos C, Nasrallah IM. Stages of tau aggregation associated with amyloidosis reflected in non‐negative matrix factorization components. Alzheimers Dement 2020. [DOI: 10.1002/alz.046728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
145
|
Ohm DT, Peterson C, Lobrovich R, Bahena A, Gibbons GS, Wolk DA, Grossman M, Lee EB, Trojanowski JQ, Irwin DJ. Preferential degeneration of the locus coeruleus in tauopathies relative to TDP‐43 proteinopathies. Alzheimers Dement 2020. [DOI: 10.1002/alz.045904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
146
|
Collins JA, Ezzo R, Vemuri P, Borowski BJ, Iaccarino L, Joie R, Lesman‐Segev OH, Bourakova V, Eloyan A, Aisen PS, Fagan AM, Foroud TM, Gatsonis C, Jack CR, Kramer JH, Koeppe RA, Saykin AJ, Toga AW, Day GS, Graff‐Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez MF, Onyike CU, Rogalski EJ, Salloway SP, Wolk DA, Wingo TS, Carrillo MC, Apostolova LG, Rabinovici GD, Dickerson BC. Neurodegeneration in the Longitudinal Evaluation of Early Onset Alzheimer’s Disease Study (LEADS) sample: Results from the MRI core. Alzheimers Dement 2020. [DOI: 10.1002/alz.046338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
147
|
McCollum L, Das SR, Wang J, Xie L, de Flores R, Wisse L, Xie SX, Yushkevich P, Wolk DA. Cognitive and neurodegenerative profile differences between “mismatch MCI” (A+T‐N+ MCI) And “prodromal AD” (A+T+N+ MCI) increase with time. Alzheimers Dement 2020. [DOI: 10.1002/alz.046030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
148
|
Dong M, Xie L, Das SR, Wolk DA, Yushkevich PA. Detecting biological changes in longitudinal MRI scans of Alzheimer’s disease patients in the hippocampus region with deep learning. Alzheimers Dement 2020. [DOI: 10.1002/alz.046453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
149
|
Dong M, Xie L, Wang J, Das SR, Wolk DA, Yushkevich P. Sensitive biomarkers to Alzheimer's disease progression in longitudinal MRI from deep learning. Alzheimers Dement 2020. [DOI: 10.1002/alz.047700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
150
|
Ravikumar S, Wisse L, Xie L, Ittyerah R, Das SR, Detre JA, Grossman M, Lavery M, Lim SA, Irwin DJ, Schuck T, Trojanowski JQ, Artacho‐Perula E, Martin MMIDO, Lee EB, Mizsei G, Tisdall DM, del Mar Arroyo Jimenez M, Munoz M, Gonzalez JCD, Parada MC, de la Rosa Prieto C, Sanchez SC, Prabhakaran K, del Pilar Marcos Rabal M, Romero FJM, Robinson JL, Wolk DA, Insausti R, Yushkevich PA. Novel ex vivo MRI atlas of the medial temporal lobe can be used to characterize structural changes due to Alzheimer’s disease pathology. Alzheimers Dement 2020. [DOI: 10.1002/alz.041279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|